Our Purpose
The Clinical Proteomics Platform aims to exploit the latest technological developments in mass spectrometry and immunoassay for the discovery, validation and use of biomarkers in various human pathologies (proteins, RNA, DNA, metabolites).
Our Approach
Several technological approaches oriented towards the use of clinical samples and high throughput are available, including mass spectrometry (MRM and HRMS) and ultra-sensitive immunoassays (SIMOA and MSD).
Our Mission
Integrated in the Montpellier Proteome Cluster since its creation and IBiSA labeled, its mission is equally to make medical, biological and technical expertise in Clinical Proteomics available to academic and industrial teams. The PPC has been ISO 9001 certified since 2014.
Latest news :
Proteomics workshop
On March 12, we organized a Biocampus workshop with the PPM, discussing the present and future of clinical proteomics. This workshop included some interesting topics such as: - Deciphering the different proteomic analysis workflows, with their constraints and...
ADPD 2024 in Lisbon
The PPC is in Lisbon !! Our Christophe Hirtz gave an oral presentation on friday : are synuclein's proteoforms good biomarkers of synucleinopathies (and how to quantify them)? Many thanks to Shimadzu Scientific Instruments for our fruitfull collaboration ! Also, our...
Dr. Koichi Tanaka visits the PPC
Last Friday, we were honored to welcome Dr. Koichi Tanaka (SHIMADZU- Koichi Tanaka Mass Spectrometry Research Laboratory), co-winner of the 2002 Nobel Prize in Chemistry, in our laboratory. It was an exciting occasion, with multiple presentations and interesting...
The PPC in a nutshell :
Employees
Years of experience
Ongoing projects
Patents
Clinical Proteomics Platform
Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5
FRANCE